Deucravacitinib
1 Inquiries
1609392-27-9
Industrial Grade
99%
25kg/Cardboard Drum
Yes
2024-06-30
Dyes,Textile agent,Medical intermediate,API,Pigments,Basic Chemicals
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceDeucravacitinib (trade name Sotykto) is a first-in-class tyrosine kinase 2 (TYK2) inhibitor recently approved for the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic inflammatory skin disease characterized by the formation of red patches and scaling on the skin. Discovered by Bristol Myers Squibb (BMS), deuterated colestitinib, also known as BMS-986165, is the first JAK inhibitor containing deuterium and the first approved selective TYK2 inhibitor, showing more than 50,000-fold selectivity over JAK1, JAK2 and JAK3.
Deucravacitinib, a highly selective allosteric TYK2 inhibitor, received its first approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy protein and lipid kinases and pseudokinases with the exception of BMPR2 (IC50 = 193 nM) and JAK1 JH2 pseudokinase domain (IC50 = 1 nM). Despite its potent affinity for JAK1 JH2, deucravacitinib elicited low functional activity in a JAK1/JAK3-dependent IL-2 stimulated cellular assay. BMS-986202 displays >10,000-fold selectivity for TYK2 JH2 over a diverse panel of 273 kinases and pseudokinases that include JAK family members. Like deucravacitinib, its high binding affinity to JAK1 JH2 (IC50 = 7.8 nM) did not translate to functional activity in the cellular assay.Basic Info-
Product Name:
Deucravacitinib
Other Name:Tyk2-IN-4;TYK2-IN-4;BMS986165;BMS-986165;BMS 986165;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Deucravacitinib;Deucravacitinib(BMS986165);Deucravacitinib (TYK2-IN-4;6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide;DeucravacitinibQ: What is Deucravacitinib Q: What is the CAS Number of Deucravacitinib
CAS No.:1609392-27-9
Molecular Formula:C20H22N8O3
InChIKeys:BZZKEPGENYLQSC-UHFFFAOYSA-N
Molecular Weight:422.45
Exact Mass:425.20031683
UNII:N0A21N6RAU
Color/Form:Off-white to light yellow
Categories:
Characteristics-
Critical Temperature & Pressure:
Store at -20°C
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Dyes,Textile agent,Medical intermediate,API,Pigments,Basic Chemicals
-
Location:
Room 507, Dongnan Technology R&D Center, No.438 Jincheng Road, Beigan Street, Xiaoshan District,Hangzhou City,Zhengjiang Province,China
-
Payment Terms:
TT against copy of documents,L/C,100% TT in advance
-
Average lead Time:
20 days
-
Total Annual Revenue:
$25 million-$50 million
-
Total Employees:
51-100
-
Year of Establishment:
2013
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted
India
Deucravacitinib
10 G Aug 18, 2026 Post an enquiry for this product
More from this Seller
-
-
-
ACS-PNZ-PYRROLIDYL-(BOC)-NSO2NH2
pharmaceutical grade / 98%
-
-
-
-
Isophthalic acid
pharmaceutical grade / 98%
-
-
-
-
3-Ethoxy-3-iminopropanoic acid ethyl ester hydrochloride
pharmaceutical grade / 98%
-
-
-
-
1,3,5-Trimethoxybenzene
Industrial Grade / 99%
-
-
-
-
4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-
pharmaceutical grade / 98%
-






